title: Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes.
abstract: The goal of this study was to verify the effect of specific treatment on parasitological and histopathological parameters in mice experimentally infected with different Trypanosoma cruzi clonal genotypes. Twenty cloned stocks were selected, representative of the whole phylogenetic diversity of the protozoan and belonging to the clonal genotypes 19 and 20 (T. cruzi I) and 39 and 32 (T. cruzi II). The stocks were inoculated in 40 BALB/c mice divided into four groups: (i) treated with benznidazole, (ii) treated with itraconazole and (iii and iv) untreated control groups (NT) for each drug, respectively. Seven parameters related to parasitaemia curves and histopathological lesions were analysed. Four during the acute phase (AP) and three during both the AP and chronic phase (CP) of infection. Statistical comparison between benznidazole-treated and NT groups for the biological parameters showed significant differences for all genotypes. Benznidazole treatment led to lower patent period, maximum of parasitaemia, day of maximum parasitaemia and area under the parasitaemia curve for all genotypes analysed. Percentage of positive haemoculture during AP and CP was lower for genotypes 19 and 32. Tissue parasitism (TP) and inflammatory process (IP) during AP were lower for genotypes 19 and 32, respectively. In general, itraconazole treatment induced a smaller reduction in these same parameters between treated and NT animals in relation to benznidazole treatment. Our results indicate that phylogenetic divergence among T. cruzi clonal genotypes must be taken in account in chemotherapy and studies dealing with all aspects of the parasite and the disease.
authors.affiliation: Departamento de Análises Clínicas, Centro de Ciências da Saúde, Bloco I-90, Universidade Estadual de Maringá, Av. Colombo, 5790, 87020-900, Maringá, PR. mjotoledo@uem.br
authors.forename: M J O
authors.initials: MJ
authors.lastname: Toledo
authors.forename: M T
authors.initials: MT
authors.lastname: Bahia
authors.forename: V M
authors.initials: VM
authors.lastname: Veloso
authors.forename: C M
authors.initials: CM
authors.lastname: Carneiro
authors.forename: G L L
authors.initials: GL
authors.lastname: Machado-Coelho
authors.forename: C F
authors.initials: CF
authors.lastname: Alves
authors.forename: H R
authors.initials: HR
authors.lastname: Martins
authors.forename: R E
authors.initials: RE
authors.lastname: Cruz
authors.forename: W L
authors.initials: WL
authors.lastname: Tafuri
authors.forename: M
authors.initials: M
authors.lastname: Lana
mesh_terms: D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D014355:Chagas Disease / Q000097:blood / Q000188:drug therapy* / Q000469:parasitology*; D003001:Cloning, Molecular; D005260:Female; D005838:Genotype; D006321:Heart / Q000469:parasitology; D007249:Inflammation / Q000473:pathology; D017964:Itraconazole / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D009206:Myocardium / Q000473:pathology; D009593:Nitroimidazoles / Q000627:therapeutic use; D014349:Trypanosoma cruzi / Q000235:genetics*; D014566:Urogenital System / Q000469:parasitology / Q000473:pathology
chemical_list: D000981:Antiprotozoal Agents; D009593:Nitroimidazoles; D017964:Itraconazole; C009999:benzonidazole